Kidney DiseasesNCT06872060
The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
A study testing Glucagon, Glucagon+Exendin9-39 and Sodium chloride in people with Kidney Diseases, run by Bispebjerg Hospital.
Trial summary
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels. Read more about this study
- Who is it for?
- Ages 20 to 60 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Kidney Diseases
- What is being tested?
- Glucagon, Glucagon+Exendin9-39 and Sodium chloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 10 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2026to 1 Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Normal health confirmed through; Interview and Medical examination
- Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes
- Informed consent
Who cannot join
- Immunosuppressive treatment in the previous 12 months
- Alcohol abuse
- Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism
- Use of lithium
- Medical treatment that affects insulin secretion or the renin-angiotensin-aldosterone system
- Liver disease (ALT > 2x normal value)
Show all 10Show fewer
- Renal impairment (serum creatinine > 130 µM and/or albuminuria)
- Individuals with severe claustrophobia
- Individuals with MR-incompatible foreign bodies
- Individuals with hypertension
About this study
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels. It has been shown to affect renal function, including electrolyte balance and blood flow, especially in conditions like type 2 diabetes where abnormal glucagon levels are common. The study aims to understand how glucagon affects regional blood flow in the kidneys, specifically the cortex and medulla, and whether these effects are mediated by glucagon receptors.
The study will be conducted on 10 healthy male participants aged 20-60 years. It involves three test days where participants will receive either glucagon, glucagon with a GLP-1 receptor antagonist, or placebo. Blood flow, glomerular filtration rate, and other renal functions will be measured using MRI. The study seeks to clarify whether glucagon's effects on the kidneys are linked to changes in regional blood flow and to determine if these effects are mediated solely by glucagon receptors.
- Conditions
- Kidney Diseases
- Being tested
- Glucagon, Glucagon+Exendin9-39, Sodium chloride
- Medical subject headings
- Kidney Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GlucagonDrug
Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes.
Glucagon+Exendin9-39Drug
Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes, plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes
Sodium chlorideDrug
Placebo (0.9% NaCl).
| Study group | Role | What they receive |
|---|---|---|
| Glucagon | Experimental | Not described Receives: Drug: Glucagon; Drug: Glucagon+Exendin9-39; Drug: Sodium chloride |
| Glucagon+Exendin9-39 | Experimental | Not described Receives: Drug: Glucagon; Drug: Glucagon+Exendin9-39; Drug: Sodium chloride |
| Sodium chloride (Placebo comparator) | Placebo comparator | Not described Receives: Drug: Glucagon; Drug: Glucagon+Exendin9-39; Drug: Sodium chloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood perfusion of the kidney
we would like to measure blood perfusion of the kidneys over time
Measured: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
Secondary outcomes (2)
Blood flow of the renal arteries
Measured: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
blood oxygen saturation of the kidneys
Measured: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2025
- Study start1 Jun 2026 (estimated)
- Primary completion1 Nov 2027 (estimated)
- Study completion1 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bispebjerg Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Asmar, Bispebjerg Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06872060
- Sponsor's protocol ID
- H-24012271
- Status last verified
- Sep 2025
- First submitted
- 21 Feb 2025
- Last updated
- 3 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
- ClinicalTrials.gov ID
- NCT06872060
- Acronym / sponsor ID
- H-24012271
- Conditions
- Kidney Diseases
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Bispebjerg HospitalUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 1 Nov 2027 (estimated)
- Study completion
- 1 Nov 2027 (estimated)
- First posted
- 12 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels. It has been shown to affect renal function, including electrolyte balance and blood flow, especially in conditions like type 2 diabetes where abnormal glucagon levels are common. The study aims to understand how glucagon affects regional blood flow in the kidneys, specifically the cortex and medulla, and whether these effects are mediated by glucagon receptors.
The study will be conducted on 10 healthy male participants aged 20-60 years. It involves three test days where participants will receive either glucagon, glucagon with a GLP-1 receptor antagonist, or placebo. Blood flow, glomerular filtration rate, and other renal functions will be measured using MRI. The study seeks to clarify whether glucagon's effects on the kidneys are linked to changes in regional blood flow and to determine if these effects are mediated solely by glucagon receptors.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Glucagon | Experimental | Drug: Glucagon, Drug: Glucagon+Exendin9-39, Drug: Sodium chloride |
| Glucagon+Exendin9-39 | Experimental | Drug: Glucagon, Drug: Glucagon+Exendin9-39, Drug: Sodium chloride |
| Sodium chloride (Placebo comparator) | Placebo comparator | Drug: Glucagon, Drug: Glucagon+Exendin9-39, Drug: Sodium chloride |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Normal health confirmed through; Interview and Medical examination
- Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes
- Informed consent
Key exclusion criteria (10 listed)
- Immunosuppressive treatment in the previous 12 months
- Alcohol abuse
- Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism
- Use of lithium
- Medical treatment that affects insulin secretion or the renin-angiotensin-aldosterone system
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GlucagonGlucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes. | Drug | Glucagon, Glucagon+Exendin9-39, Sodium chloride (Placebo comparator) |
| Glucagon+Exendin9-39Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes, plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes | Drug | Glucagon, Glucagon+Exendin9-39, Sodium chloride (Placebo comparator) |
| Sodium chloridePlacebo (0.9% NaCl). | Drug | Glucagon, Glucagon+Exendin9-39, Sodium chloride (Placebo comparator) |
Primary outcome
Blood perfusion of the kidney
Time frame: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
we would like to measure blood perfusion of the kidneys over time
2 secondary outcomes
Blood flow of the renal arteries
Time frame: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
blood oxygen saturation of the kidneys
Time frame: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Kidney Diseases
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Glucagon, Glucagon+Exendin9-39 and Sodium chloride in people with Kidney Diseases, run by Bispebjerg Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood perfusion of the kidney (time frame: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2025.